Aad Liefveld
Fellow | Advisory Board Member, Link2Trials and Member, BEAMER project team
Belmont Collaborative for Health Systems Innovation
Biography
Aad is a member of the advisory board at Link2Trials and since 2021 actively involved in the BEAMER project.
BEAMER is a European Union (EU) co-funded initiative of the European Federation of Pharmaceutical Industries and Associations (EFPIA) to better understand the actionable key factors that influence patient adherence behavior across disease areas and deliver guidance that various stakeholders can use to address patients’ needs and boost adherence to treatment.
Aad has always been a strong advocate of what the pharmaceutical industry is focusing on today: patient centricity and patient experience. And already in 2017, Aad developed the Adherence Risk Management services (ARM) for Link2Trials to improve patient adherence and experience during clinical trials.
ARM uses the human behavioral based Subjective Health Experience model developed by his BEAMER colleague Prof Dr. Sjaak Bloem of the Nyenrode Business University in the Netherlands.